Illumina Announces New Multiomics Oncology Breakthroughs Using Spatial Transcriptomics, 5-Base Sequencing and Proteomics

Reuters02-25

<a href="https://laohu8.com/S/ILMN">Illumina</a> Announces New Multiomics Oncology Breakthroughs Using Spatial Transcriptomics, 5-Base Sequencing and Proteomics

Illumina Inc. announced customer clinical research using its 5-base sequencing solution to support pediatric kidney cancer studies, aiming to improve detection of rare tumors such as Wilms and rhabdoid cancers by combining genomic and methylation profiling. The company also highlighted multiomic research in adnexal masses related to advanced ovarian cancer, using its 5-base solution, Illumina Protein Prep, and Illumina Spatial Technology to differentiate malignant from benign samples and to investigate localized tumor biology. Illumina said these findings were revealed by researchers at the Advances in Genome Biology and Technology annual meeting (AGBT).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602250915PR_NEWS_USPR_____LA95329) on February 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614013038?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 22:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614013038","market":"fut","top_or_hot":-1,"title":"Illumina Announces New Multiomics Oncology Breakthroughs Using Spatial Transcriptomics, 5-Base Sequencing and Proteomics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ILMN\">Illumina</a> Announces New Multiomics Oncology Breakthroughs Using Spatial Transcriptomics, 5-Base Sequencing and Proteomics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ILMNV\">Illumina Inc</a>. announced customer clinical research using its 5-base sequencing solution to support pediatric kidney cancer studies, aiming to improve detection of rare tumors such as Wilms and rhabdoid cancers by combining genomic and methylation profiling. The company also highlighted multiomic research in adnexal masses related to advanced ovarian cancer, using its 5-base solution, Illumina Protein Prep, and Illumina Spatial Technology to differentiate malignant from benign samples and to investigate localized tumor biology. Illumina said these findings were revealed by researchers at the Advances in Genome Biology and Technology annual meeting (AGBT).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602250915PR_NEWS_USPR_____LA95329) on February 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Illumina Announces New Multiomics Oncology Breakthroughs Using Spatial Transcriptomics, 5-Base Sequencing and Proteomics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIllumina Announces New Multiomics Oncology Breakthroughs Using Spatial Transcriptomics, 5-Base Sequencing and Proteomics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-25 22:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ILMN\">Illumina</a> Announces New Multiomics Oncology Breakthroughs Using Spatial Transcriptomics, 5-Base Sequencing and Proteomics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ILMNV\">Illumina Inc</a>. announced customer clinical research using its 5-base sequencing solution to support pediatric kidney cancer studies, aiming to improve detection of rare tumors such as Wilms and rhabdoid cancers by combining genomic and methylation profiling. The company also highlighted multiomic research in adnexal masses related to advanced ovarian cancer, using its 5-base solution, Illumina Protein Prep, and Illumina Spatial Technology to differentiate malignant from benign samples and to investigate localized tumor biology. Illumina said these findings were revealed by researchers at the Advances in Genome Biology and Technology annual meeting (AGBT).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602250915PR_NEWS_USPR_____LA95329) on February 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL3Pzrv6:1","article_id":"2614013038","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614013038","pubTimestamp":1772028919,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Illumina Inc. announced customer clinical research using its 5-base sequencing solution to support pediatric kidney cancer studies, aiming to improve detection of rare tumors such as Wilms and rhabdoid cancers by combining genomic and methylation profiling. The company also highlighted multiomic research in adnexal masses related to advanced ovarian cancer, using its 5-base solution, Illumina Protein Prep, and Illumina Spatial Technology to differentiate malignant from benign samples and to investigate localized tumor biology. Illumina said these findings were revealed by researchers at the Advances in Genome Biology and Technology annual meeting .","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","TXG":"10x Genomics, Inc.","BK4548":"巴美列捷福持仓","BK4588":"碎股","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4534":"瑞士信贷持仓","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓","ILMN":"Illumina"},"translate_title":"Illumina宣布使用空间转录组学、5碱基测序和蛋白质组学的多组学肿瘤学新突破","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TXG":0.9,"ILMN":0.9},"content_text":"Illumina Announces New Multiomics Oncology Breakthroughs Using Spatial Transcriptomics, 5-Base Sequencing and Proteomics\n    \n\nIllumina Inc. announced customer clinical research using its 5-base sequencing solution to support pediatric kidney cancer studies, aiming to improve detection of rare tumors such as Wilms and rhabdoid cancers by combining genomic and methylation profiling. The company also highlighted multiomic research in adnexal masses related to advanced ovarian cancer, using its 5-base solution, Illumina Protein Prep, and Illumina Spatial Technology to differentiate malignant from benign samples and to investigate localized tumor biology. Illumina said these findings were revealed by researchers at the Advances in Genome Biology and Technology annual meeting (AGBT).\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602250915PR_NEWS_USPR_____LA95329) on February 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614013038","isCrawlerRequest":true}